Modelled DT Structure
Method: multi-sequence alignment based machine learning
Detail: Structure Info
| General Information of DT | |||||
|---|---|---|---|---|---|
| DT ID | DTD0499 | ||||
| Gene Name | SLCO1C1 | ||||
| Protein Name | Organic anion transporting polypeptide 1C1 | ||||
| Gene ID | |||||
| UniProt ID | |||||
| TCDB ID | |||||
| 3D Structure |
Modelled DT Structure Method: multi-sequence alignment based machine learning Detail: Structure Info |
||||
| Synonyms | OAT-RP-5; OATP-14; OATP-F; OATP14; OATP1C1; OATPF; OATPRP5; Organic anion transporter F; Organic anion transporter polypeptide-related protein 5; Organic anion-transporting polypeptide 14; SLC21A14; SLCO1C1; Solute carrier family 21 member 14; Solute carrier organic anion transporter family member 1C1; Thyroxine transporter | ||||
| DT Family | Organo Anion Transporter (OAT) Family ; | ||||
| Tissue Specificity | Highly expressed in brain and in Leydig cellsin testis. Detected in many brain regions with the exception ofpons and cerebellum. Not strongly enriched in cerebralmicrovessels. | ||||
| Function | This Na(+)-independent transporter mediates the organic anions such as the thyroid hormones thyroxine (T4) and rT3 and may play a signifiant role in regulating T4 flux into and out of the brain. Other potential substrates, such as triiodothyronine (T3), 17-beta-glucuronosyl estradiol, estrone-3-sulfate and sulfobromophthalein (BSP) are transported with much lower efficiency. | ||||
| Disease(s) | Medical abortion [ICD-11: JA00.1] | ||||
| Endogenous Substrate(s) | Organoanions; Thyroid hormones | ||||
| Variability Data of This Drug Transporter (DT) | |||||
|
Regulatory Variability Data of This DT (VARIDT 3.0) |
|||||
|
(β) Post-translational Modification of This DT |
|||||
|
(ε) Exogenous Modulation of This DT |
|||||
|
Structural Variability Data of This DT (VARIDT 2.0) |
|||||
|
(β) Inter-species Structural Differences |
|||||
|
General Variability Data of This DT (VARIDT 1.0) |
|||||
|
(α) Genetic Polymorphisms of This DT |
|||||
|
(β) Disease-specific Protein Abundances of This DT |
|||||
|
(γ) Species- and Tissue-specific DT Abundances |
|||||
| Molecular Transporting Profile of This DT | |||||
|
Full List of Drug(s) Transported by This DT |
|||||
|
Approved Drug |
Click to Show/Hide the Full List of Drug: 3 Drugs in Total | ||||
| Drug Name | Highest Status | Detail | Indication | ICD 11 | Ref |
|
Dinoprostone
|
Approved | Drug Info | Medical abortion | JA00.1 | [1] |
|
Levothyroxine
|
Approved | Drug Info | Hypothyroidism | 5A00.2 | [1] |
|
Liothyronine
|
Approved | Drug Info | Hypothyroidism | 5A00.2 | [2] |
|
Drug-DT Affinity Assessed by Cell Line |
|||||
|
Approved Drug |
Click to Show/Hide the Full List of Drug: 1 Drugs in Total | ||||
| Drug Name | Highest Status | Detail | Cell Line | Affinity | Ref |
| Levothyroxine | Approved | Drug Info | Chinese hamster ovary (CHO) cells-OATP1C1 | Km = 0.0904 microM | [1] |
| References | |||||
| 1 | Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol. 2002 Oct;16(10):2283-96. | ||||
| 2 | Involvement of multispecific organic anion transporter, Oatp14 (Slc21a14), in the transport of thyroxine across the blood-brain barrier. Endocrinology. 2004 Sep;145(9):4384-91. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.